Can Viridian Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 15.15 — current assets exceed current liabilities.

Where does Viridian Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Viridian Therapeutics, Inc. VRDN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$212.38M+113%	$99.59M-3.1%	$102.83M-33.9%	$155.58M+268%
Short-term investments	$662.27M+7.2%	$617.99M+65.0%	$374.54M+39.3%	$268.97M+73.9%
Prepaid expenses and other current assets	$19.58M-6.2%	$20.88M+132%	$9.01M+38.1%	$6.52M+137%
Derivative assets	$20.03M—	——	——	——
Total current assets	$894.23M+21.1%	$738.46M+51.8%	$486.48M+12.8%	$431.17M+115%
Property and equipment, net	$1.23M-0.6%	$1.24M-26.1%	$1.67M+26.1%	$1.33M+254%
Operating lease right-of-use assets	$2.42M+9.8%	$2.21M+32.0%	$1.67M+3.7%	$1.61M-4.2%
Other non-current assets	$1.54M+207%	$501K-17.1%	$604K-38.5%	$982K-34.1%
Total assets	$899.42M+21.1%	$742.4M+51.4%	$490.42M+12.7%	$435.09M+114%
Accounts payable	$8.68M+305%	$2.14M-4.3%	$2.24M-84.3%	$14.23M+511%
Accrued expenses	$19.66M-57.0%	$45.73M+89.7%	$24.11M+28.1%	$18.83M+70.9%
Deferred revenue	$367K+27.4%	$288K0.0%	$288K0.0%	$288K-0.3%
Operating lease liabilities, current	$753K+46.8%	$513K-39.1%	$843K+37.5%	$613K+17.9%
Accrued interest	$385K+150%	$154K0.0%	$154K+295%	$39K—
Total current liabilities	$70.7M+47.7%	$47.87M+79.7%	$26.64M-20.1%	$33.35M+145%
Long-term debt	$34.24M—	$0-100%	$20.21M+335%	$4.65M—
Other non-current liabilities	$2.34M+1.4%	$2.31M+133%	$989K-15.6%	$1.17M-3.0%
Total liabilities	$20.03M-71.7%	$70.76M+46.2%	$48.4M+20.9%	$40.03M+150%
Common stock	200M+24,591%	810K+50.0%	540K+30.4%	414K+73.2%
Additional paid-in capital	$1.93B+30.4%	$1.48B+53.9%	$960.54M+29.6%	$741.07M+79.8%
Retained earnings	-$1.34B-34.4%	-$995.86M-37.2%	-$725.91M-48.7%	-$488.17M-36.2%
Accumulated other comprehensive income (loss)	$447K+4,570%	-$10K-103%	$338K+187%	-$390K-148%
Total stockholders' equity	$722.17M+7.5%	$671.64M+51.9%	$442.02M+11.9%	$395.06M+110%
Total liabilities and stockholders' equity	$899.42M+21.1%	$742.4M+51.4%	$490.42M+12.7%	$435.09M+114%
Available-for-Sale Debt Securities - Amortized Cost	$661.82M-7.3%	$714.06M+54.3%	$462.91M+9.0%	$424.84M+116%
Cash, Cash Equivalents, and Marketable Securities	$662.27M-7.3%	$714.05M+54.1%	$463.25M+9.1%	$424.45M+116%
Available For Sale Securities Debt Securities Current	$662.27M+7.2%	$617.99M+65.0%	$374.54M+39.3%	$268.97M+73.9%
Cash Cash Equivalents And Short Term Investments	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$1.54M+207%	$501K-17.1%	$604K-38.5%	$982K-34.1%
Investments - Amortized Cost Basis	$661.82M-7.3%	$714.06M+54.3%	$462.91M+9.0%	$424.84M+116%
Net Investment in Lease	$2.42M+9.8%	$2.21M+32.0%	$1.67M+3.7%	$1.61M-4.2%
Operating lease right-of-use assets	$2.42M+9.8%	$2.21M+32.0%	$1.67M+3.7%	$1.61M-4.2%
Other non-current assets	$1.54M+207%	$501K-17.1%	$604K-38.5%	$982K-34.1%
Operating Lease Right-of-Use Assets in Other Assets	$2.42M+9.8%	$2.21M+32.0%	$1.67M+3.7%	$1.61M-4.2%
Software and Technology Licenses, Net	$1.54M+207%	$501K-17.1%	$604K-38.5%	$982K-34.1%
Accrued Manufacturing Costs	$19.66M+84.8%	$10.64M+1.2%	$10.51M+120%	$4.77M+30.7%
Other Commercial Liabilities	$62.01M+35.6%	$45.73M+89.7%	$24.11M+28.1%	$18.83M+70.9%
Accrued Liabilities, Current	$62.01M+35.6%	$45.73M+89.7%	$24.11M+28.1%	$18.83M+70.9%
Compensation and benefits	$19.66M+84.8%	$10.64M+1.2%	$10.51M+120%	$4.77M+30.7%
Derivative Liabilities - Fair Value	$20.03M—	$0—	——	——
Professional Service Fees Payable	$3.83M+64.7%	$2.32M+391%	$473K+20.7%	$392K+180%
Derivative Liabilities (Non-Current)	$20.03M—	$0—	——	——
Total debt	$36.96M+1,357%	$2.54M-88.5%	$22.04M+246%	$6.37M+1,125%
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	101.8M+25.7%	81M+50.0%	54M+30.7%	41.3M+72.7%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1.02M+25.7%	$810K+50.0%	$540K+30.4%	$414K+73.2%
Share-Based Payment Award Options Outstanding - Number	——	——	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	——	——	——	——
Unrealized Gains on Investments	$495K-11.1%	$557K+30.1%	$428K+245%	$124K+1,967%
Unrealized Losses on Investments (Before Tax)	$48K-91.5%	$567K+530%	$90K-82.5%	$514K+215%
Gross Assets/Liabilities	$20.03M—	——	——	——
Accrued milestone payment	$10M—	——	——	——
Accrued outsourced clinical and nonclinical studies	$8.6M-25.8%	$11.59M—	——	——
Accrued outsourced manufacturing	$15.99M-17.5%	$19.37M—	——	——
Professional service fees	$3.83M+64.7%	$2.32M+391%	$473K+20.7%	$392K+180%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$48K-91.5%	$567K+530%	$90K-82.5%	$514K+215%
Gross Unrealized Gains	$495K-11.1%	$557K+30.1%	$428K+245%	$124K+1,967%
Total	$661.82M-7.3%	$714.06M+54.3%	$462.91M+9.0%	$424.84M+116%
Available for sale investments	$662.27M-7.3%	$714.05M+54.1%	$463.25M+9.1%	$424.45M+116%
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%
Common stock, shares issued (in shares)	$101.83M+25.7%	$80.99M+50.0%	$53.99M+30.7%	$41.31M+72.7%
Common Stock, Shares, Outstanding	$101.83M+25.7%	$80.99M+50.0%	$53.99M+30.7%	$41.31M+72.7%
Derivative Liability	$20.03M—	——	——	——
Derivative Liability, Noncurrent	$20.03M—	$0—	——	——
Cost not yet recognized	——	——	——	——
Other accrued liabilities	$2.44M+184%	$860K-4.7%	$902K+471%	$158K-24.8%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	——	——	——	——
Incentive stock program, shares reserved for future grants (in shares)	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Viridian Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 15.15 — current assets exceed current liabilities.
Where does Viridian Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.